
ESTA Stock Forecast & Price Target
ESTA Analyst Ratings
Bulls say
Establishment Labs Hldgs is benefiting from accelerating U.S. Motiva adoption, with August 2026 survey data showing ~23% share as of 2Q26 versus a 12% projection from April 2024, while 58% of surveyed surgeons now actively use Motiva and expect share to rise further. The company’s growth case is reinforced by strong operating momentum, including Q2 revenue of $67.5M (+32% y/y), fourth consecutive quarter of positive adjusted EBITDA at $3.7M, and raised full-year 2026 revenue guidance to $269M-$271M. Its disruptive implant technology, expanding minimally invasive platform, and pipeline opportunities such as Preservé, reconstruction label expansion, and GEM support a longer-term path to stronger revenue growth and free cash flow.
Bears say
Establishment Labs Hldgs is viewed negatively because the company still faces substantial execution and industry risks despite Motiva’s share gains. The excerpts note that Allergan and Mentor are expected to keep ceding share across the forecast horizon, while Tiger Aesthetics remains at only about 2% share and Bimini Health Tech is not expected to gain traction, underscoring a concentrated competitive landscape. Even with above-average revenue growth and attractive gross margin, the business remains exposed to recession risk, competition, funding needs, product-launch failures, tariffs, and intellectual property issues.
This aggregate rating is based on analysts' research of Establishment Labs Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ESTA Analyst Forecast & Price Prediction
Start investing in ESTA
Order type
Buy in
Order amount
Est. shares
0 shares